Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 936559

Drug Profile

BMS 936559

Alternative Names: Anti PD L1; BMS-936559; MDX-1105; PD-L1 inhibitor - Bristol-Myers Squibb

Latest Information Update: 28 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex
  • Class Antineoplastics; Antiretrovirals; Antiseptics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies; HIV infections; Sepsis; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 14 Sep 2017 Bristol-Myers Squibb terminates due to change in business objectives its phase I/II trial in Sepsis in USA (IV, Infusion) (NCT02576457)
  • 22 Feb 2016 Pharmacokinetics and adverse event results from a phase I trial in HIV Infections presented at 23rd Conference on Retroviruses and Opportunistic Infections (CROI-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top